|
Kas1, PFE has a very high P/E (over 59, I think), but analyst expects sales of Viagra to be over $2 billion in 2 or 3 years, and PFE has over 20 new drugs in the pipeline, and besides the blockbuster sales of Viagra, PFE is also co-marketing Lipitor, WLA's blockbuster anti-cholesterol drug. If I have to pick a pharmaceutical company to invest in, I'll pick PFE, but LLY is a definite buy anytime it is in the low 60's, and it will go to new highs on the strength of the coming news about Evista (and the good news about the sales of Zyprexa). Breast cancer ranks number 1 as cause of death for women age 40 to 65. If Evista is approved for prevention of breast cancer, there should be a large market for this drug. |
